… intrinsic EGFR tyrosine kinase activity and triggers autophosphorylation of specific tyrosine
residues … Clinical parameters of patients treated with tyrosine kinase inhibitors as a function of …

… to tyrosine TKI therapy appears to be associated with certain molecular and clinical … model
with readily available clinical parameters to make it easily applicable in clinical practice, this …

… At clinical progression, 64 (55%) EGFR T790M plasma positive patients were subjected to
second line-treatment with osimertinib and strictly monitored during the first month of therapy. …

… factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib, but others do
not. Clinical parameters alone are not sufficient to identify which patients are likely to benefit. …

… parameters and correlations between EGFR genotype and response to … of clinical studies,
performed following the initial identification of specific mutations in the EGFR tyrosine kinase …

… None of the changes in laboratory parameters, vital signs, and physical examination were
thought clinically significant. While patients had sporadic hematological and clinical chemistry …

… receptor (EGFR) gene are predictive for favorable response to tyrosine kinase inhibitors (TKIs…
and KRAS mutations were mutually exclusive, and the clinical-pathologic characteristics of …

… of the epidermal growth factor receptor (EGFR) are the most … better clinical outcomes following
treatment with EGFR-tyrosine … clinical efficacy of EGFR-TKIs in NSCLC patients harboring …

… The concentrations of circulating DNA in the plasma samples ranged between 7.4 and 4,768
ng/ml (median 30.7 ng/mL) and were not correlated to gender or clinical parameters such …

… those with EGFR-WT when receiving tyrosine kinase inhibitors (… receptor (EGFR) directly
affected the effectiveness of EGFR TKIs… Among clinical parameters, SUVmax and mutation sites …